David E. I. Pyott - 18 Feb 2026 Form 3 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Reporting relationship
Director
Issuer ticker
TARS
Reported as of
18 Feb 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
3
Accepted by SEC
20 Feb 2026, 16:35:33 UTC
Prior SEC filing
09 Jun 2025
Next SEC filing
28 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Scott Sieckert, Attorney-in-Fact

Key filing fact

David E. I. Pyott filed Form 3 for Tarsus Pharmaceuticals, Inc. (TARS) on 20 Feb 2026.

Key facts

  • This page summarizes David E. I. Pyott's Form 3 filing for Tarsus Pharmaceuticals, Inc. (TARS).
  • 0 reported transactions and 5 derivative rows are listed below.
  • Accepted by SEC: 20 Feb 2026, 16:35.

Change

  • Previous filing in this sequence was filed on 09 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001051578 Primary reporting owner

PYOTT DAVID E I

Relationship
Director
Address
C/O TARSUS PHARMACEUTICALS, 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Signature date
20 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TARS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
7,991
Date
18 Feb 2026
Ownership
By the David E.I. Pyott Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TARS holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,000
Exercise price
$12.97
Footnotes
F1
TARS holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,500
Exercise price
$18.27
Footnotes
F2
TARS holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,500
Exercise price
$32.76
Footnotes
F3
TARS holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,128
Exercise price
$49.97
Footnotes
F4
TARS holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,383
Exercise price
$0.000000
Footnotes
F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Option granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan (the "Plan"). The option shares vested and became exercisable on April 24, 2023.

Footnote F2

Option granted under the Plan. The option shares vested and became exercisable on August 1, 2024.

Footnote F3

Option granted under the Plan. The option shares vested and became exercisable on April 24, 2025.

Footnote F4

Option granted under the Plan. The option shares vest and become exercisable on April 24, 2026, subject to the Reporting Person's continuous service.

Footnote F5

Restricted Stock Units ("RSUs") granted under the Plan. The RSUs vest on April 24, 2026, subject to the Reporting Person's continuous service.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .